Steven Hirschfeld

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7481354/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 252-266.	2.0	445
2	H-2RIIBP, a member of the nuclear hormone receptor superfamily that binds to both the regulatory element of major histocompatibility class I genes and the estrogen response element Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 8289-8293.	7.1	298
3	Regulatory Approvals of Pediatric Oncology Drugs: Previous Experience and New Initiatives. Journal of Clinical Oncology, 2003, 21, 1066-1073.	1.6	205
4	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 491-505.	2.0	165
5	FDA Drug Approval Summaries: Oxaliplatin. Oncologist, 2004, 9, 8-12.	3.7	150
6	Paediatric drug development: The impact of evolving regulations. Advanced Drug Delivery Reviews, 2014, 73, 2-13.	13.7	124
7	New Models for Large Prospective Studies: Is There a Better Way?. American Journal of Epidemiology, 2012, 175, 859-866.	3.4	110
8	A constitutive damage-specific DNA-binding protein is synthesized at higher levels in UV-irradiated primate cells Molecular and Cellular Biology, 1990, 10, 2041-2048.	2.3	95
9	Developmental and tissue-specific expression of nuclear proteins that bind the regulatory element of the major histocompatibility complex class I gene Journal of Experimental Medicine, 1989, 169, 1309-1321.	8.5	93
10	Improving the value of clinical research through the use of Common Data Elements. Clinical Trials, 2016, 13, 671-676.	1.6	93
11	Drug Approval Summaries: Arsenic Trioxide, Tamoxifen Citrate, Anastrazole, Paclitaxel, Bexarotene. Oncologist, 2001, 6, 4-11.	3.7	86
12	Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs?. Journal of Clinical Oncology, 2009, 27, 4398-4405.	1.6	81
13	Inhibition of estrogen-responsive gene activation by the retinoid X receptor beta: evidence for multiple inhibitory pathways Molecular and Cellular Biology, 1993, 13, 2258-2268.	2.3	79
14	Global alignment of immunization safety assessment in pregnancy – The GAIA project. Vaccine, 2016, 34, 5993-5997.	3.8	72
15	Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemotherapy and Pharmacology, 1999, 44, 417-421.	2.3	49
16	Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women. Vaccine, 2016, 34, 5998-6006.	3.8	42
17	Optimized DNA extraction from neonatal dried blood spots: application in methylome profiling. BMC Biotechnology, 2014, 14, 60.	3.3	41
18	Pediatric Regulatory Initiatives. Handbook of Experimental Pharmacology, 2011, 205, 245-268.	1.8	37

STEVEN HIRSCHFELD

#	Article	IF	CITATIONS
19	Building a Common Pediatric Research Terminology for Accelerating Child Health Research. Pediatrics, 2014, 133, 516-525.	2.1	35
20	Thyroid abnormalities in children infected with human immunodeficiency virus. Journal of Pediatrics, 1996, 128, 70-74.	1.8	34
21	H-2RIIBP expressed from a baculovirus vector binds to multiple hormone response elements Molecular Endocrinology, 1992, 6, 219-230.	3.7	32
22	Oncology drug development: United States Food and Drug Administration perspective. Critical Reviews in Oncology/Hematology, 2002, 42, 137-143.	4.4	30
23	A Federated Model of IRB Review for Multisite Studies: A Report on the National Children's Study Federated IRB Initiative. IRB: Ethics & Human Research, 2014, 36, 1-6.	0.8	26
24	Use of Human Recombinant Growth Hormone and Human Recombinant Insulin-Like Growth Factor-l in Patients with Human Immunodeficiency Virus Infection. Hormone Research, 1996, 46, 215-221.	1.8	24
25	Meeting the Demand for Pediatric Clinical Trials. Science Translational Medicine, 2014, 6, 227fs11.	12.4	23
26	Inhibition of Estrogen-Responsive Gene Activation by the Retinoid X Receptor β: Evidence for Multiple Inhibitory Pathways. Molecular and Cellular Biology, 1993, 13, 2258-2268.	2.3	23
27	The National Children's Study — A Proposed Plan. New England Journal of Medicine, 2013, 369, 1873-1875.	27.0	22
28	Immunization in pregnancy clinical research in low- and middle-income countries – Study design, regulatory and safety considerations. Vaccine, 2017, 35, 6575-6581.	3.8	22
29	Challenges in clinical trials for children and young people. Archives of Disease in Childhood, 2021, 106, 321-325.	1.9	21
30	National Children's Study: Update in 2010. Mount Sinai Journal of Medicine, 2011, 78, 119-125.	1.9	20
31	Development of a Pediatric Adverse Events Terminology. Pediatrics, 2017, 139, .	2.1	20
32	Arm Span and Ulnar Length Are Reliable and Accurate Estimates of Recumbent Length and Height in a Multiethnic Population of Infants and Children under 6 Years of Age. Journal of Nutrition, 2014, 144, 1480-1487.	2.9	19
33	Longer breastfeeding duration reduces the positive relationships among gestational weight gain, birth weight and childhood anthropometrics. Journal of Epidemiology and Community Health, 2015, 69, 632-638.	3.7	18
34	Expression of major histocompatibility complex (MHC) class I genes in astrocytes correlates with the presence of nuclear factors that bind to constitutive and inducible enahcers. Journal of Neuroimmunology, 1992, 41, 35-42.	2.3	16
35	The National Children's Study: An Opportunity for Medical Toxicology. Journal of Medical Toxicology, 2012, 8, 160-165.	1.5	16
36	Dysregulation of Growth and Development in HIV-Infected Children. Journal of Nutrition, 1996, 126, 2641S-2650S.	2.9	13

STEVEN HIRSCHFELD

#	Article	IF	CITATIONS
37	Pain as a Complication of HIV Disease. AIDS Patient Care and STDs, 1998, 12, 91-108.	2.5	13
38	Pediatric Oncology: Regulatory Initiatives. Oncologist, 2000, 5, 441-444.	3.7	12
39	Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy. Cytotherapy, 2008, 10, 312-316.	0.7	11
40	Progression-free survival as an end-point in clinical trials of biotherapeutic agents. European Journal of Cancer, Supplement, 2007, 5, 23-28.	2.2	10
41	HIV-1 infected monozygotic twins: a tale of two outcomes. BMC Evolutionary Biology, 2011, 11, 62.	3.2	10
42	DEVELOPMENTAL THERAPEUTICS IN CHILDHOOD CANCER. Hematology/Oncology Clinics of North America, 2001, 15, 631-655.	2.2	9
43	Harmonizing Biomarker Measurements in Longitudinal Studies of Children's Health and the Environment. Biomonitoring, 2014, 1, .	1.0	9
44	Growth as a part of the composite endpoint in paediatric antiretroviral clinical trials. Journal of Antimicrobial Chemotherapy, 2004, 54, 701-703.	3.0	7
45	Introduction and Goals for the National Children's Study. Frontiers in Pediatrics, 2018, 5, 240.	1.9	7
46	Current Status of the National Children's Study. Epidemiology, 2010, 21, 605-606.	2.7	5
47	Frameworks for Evaluating Medicines in Children. Clinical Therapeutics, 2017, 39, 1949-1958.	2.5	5
48	Assessment of a shortened informed consent form for pediatric research: a pilot study. Pediatric Research, 2018, 84, 516-519.	2.3	5
49	Pediatric Patients and Drug Safety. Journal of Pediatric Hematology/Oncology, 2005, 27, 122-124.	0.6	4
50	History of Children and the Development of Regulations at the FDA. , 0, , 6-15.		4
51	Prerequisites to support high-quality clinical trials in children and young people. Archives of Disease in Childhood, 2021, 106, 423-428.	1.9	4
52	Working Group Session Report: Cancer. Journal of Nutrition, 1999, 129, 306S-307S.	2.9	3
53	The FDA and The Lancet : an exchange. Lancet, The, 2001, 358, 415.	13.7	3
54	The pediatric research equity act and oncology. Pediatric Blood and Cancer, 2004, 43, 99-102.	1.5	3

STEVEN HIRSCHFELD

#	Article	IF	CITATIONS
55	Sponsors meet scientists to speed pediatric medicines development. Science Translational Medicine, 2015, 7, 279fs11.	12.4	3
56	What Could the Future of Safety Monitoring Look Like?. Therapeutic Innovation and Regulatory Science, 2019, 53, 590-600.	1.6	3
57	Health Measurement Model—Bringing a Life Course Perspective to Health Measurement: The PRISM Model. Frontiers in Pediatrics, 2021, 9, 605932.	1.9	3
58	Principles of Researching Health Disparities in Longitudinal Cohort Studies Enrolling Children. Frontiers in Pediatrics, 2021, 9, 627298.	1.9	3
59	Selected issues in human immunodeficiency virus infection in adolescents. Current Opinion in Pediatrics, 1992, 4, 599-606.	2.0	2
60	Predictive Models for Characterizing Disparities in Exclusive Breastfeeding Performance in a Multi-ethnic Population in the US. Maternal and Child Health Journal, 2016, 20, 398-407.	1.5	2
61	Weight estimation among multi-racial/ethnic infants and children aged 0–5·9 years in the USA: simple tools for a critical measure. Public Health Nutrition, 2019, 22, 147-156.	2.2	2
62	Resource expectations for pediatric studies: Correlation of study type and patient number for FDA labeling. Journal of Clinical Oncology, 2008, 26, 6632-6632.	1.6	2
63	A child is a child is a child? Paediatric terminology in a health context. Developmental Medicine and Child Neurology, 2015, 57, 985-985.	2.1	1
64	Cloned Trans-Acting Factors that Bind to the Regulatory Elements of the Major Histocompatibility Complex Class I Gene. , 1990, , 125-132.		1
65	Threshold of Credibility: New Approach to Licensing Acute Leukemia Therapy Blood, 2004, 104, 3128-3128.	1.4	1
66	The Role of the FDA in Cancer Clinical Trials. , 2007, 132, 51-109.		1
67	Dealing with Death: Visions of Those Who Left Too Soon. American Journal of Nursing, 1996, 96, 57.	0.4	0
68	Threshold of Credibility: A New Approach to Product Development for Metastatic Melanoma Therapy. Journal of Immunotherapy, 2004, 27, S55.	2.4	0
69	A survey of phase I study designs of cellular, gene therapy and antigenic products for cancer at the US Food & Drug Administration. Journal of Clinical Oncology, 2005, 23, 6035-6035.	1.6	0
70	Reframing clinical trial design and intervention development Journal of Clinical Oncology, 2016, 34, e14044-e14044.	1.6	0